U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07353281) titled 'Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention' on Jan. 13.
Brief Summary: Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality worldwide, particularly among women with known risk factors. Uterotonic agents are routinely administered after vaginal delivery to prevent excessive bleeding. Carbetocin, a long-acting oxytocin analogue, and misoprostol are both used for this purpose, but comparative data in high-risk vaginal deliveries remain limited.
This prospective randomized study aims to compare the effectiveness and safety of intravenous carbetocin versus rectal misoprostol for the prev...